CDK4/6抑制剂在乳腺癌治疗中的研究进展  

Progress of CDK4/6 Inhibitor for the Treatment of Breast Cancer

作　　者：王浩[1] 田超[1] WANG Hao;TIAN Chao(Sichuan Cancer Hospital & Institute, Sichuan Cancer Center of Medicine, Chengdu Sichuan 610041, China)

机构地区：[1]四川省肿瘤医院研究所,四川省癌症防治中心,四川成都610041

出　　处：《药品评价》2017年第12期12-19,共8页Drug Evaluation

摘　　要：乳腺癌的发病率在我国女性恶性肿瘤中居首位。针对乳腺癌发生、发展有关的信号通路进行靶向药物的开发与临床应用,成为乳腺癌治疗研究的新热点。本文主要介绍了CDK4/6抑制剂在乳腺癌治疗中的机制,并对最新的临床研究进行综述。Breast cancer is the most common malignancies among women in China.Because of the better effectiveness and less side effects than chemo-and radio-therapies,targeted therapy against main signaling pathways of breast carcinogenesis and development has become one of the research focuses in breast cancer research field.In this review,we summarized current targeted therapies applied clinically and undergone clinical research about CDK4/6inhibitor in the treatment of breast cancer.

关 键 词：乳腺癌 靶向治疗 CDK4/6抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]